Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736656 · ClinicalTrials.gov registry record · Phase 3
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
A Phase 3 study of Attention Deficit/Hyperactivity Disorder, sponsored by Supernus Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,400
- Enrollment target
- 16
- Study locations
NCT02736656 is a Phase 3 study of Attention Deficit/Hyperactivity Disorder that is active but no longer recruiting, run by Supernus Pharmaceuticals. The registered enrollment target is 1,400 participants, above the 192-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (629% higher). The trial reports 16 study locations across 9 states.
The verdict
NCT02736656, a Phase 3 study of Attention Deficit/Hyperactivity Disorder, is active but no longer recruiting, sponsored by Supernus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,400 participants
- Enrollment target
- 16
- Study locations
Study Summary
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
Conditions Studied
Interventions
- DRUG SPN-812
Study Locations (16)
Florida
- Meridien Research at Florida Clinical Research Center - Bradenton
- Sarkis Clinical Trials - Gainesville
- Indago Research & Health Center, Inc. - Hialeah
- Florida Clinical Research Center, LLC. - Maitland
- Florida Clinical Research Center, LLC - Maitland
Oklahoma
- IPS Research - Oklahoma City
- Paradigm Research Professionals - Oklahoma City
Tennessee
- Clinical Neuroscience Solutions, Inc. - Memphis
- CNS Healthcare - Memphis
Texas
- Bayou City Research Corporation - Houston
- Road Runner Research - San Antonio
Arkansas
- Woodland International Research Group - Little Rock
California
- Alliance for Wellness dba Alliance for Research - Long Beach
Colorado
- MCB Clinical Research Centers, LLC - Colorado Springs
Utah
- Ericksen Research & Development - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736656
The ClinicalTrials.gov registry entry for NCT02736656 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (629% higher). The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which SPN-812 is the first listed.
NCT02736656 reports 16 study locations spanning 9 distinct geographic areas - top geographies include Florida, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02736656 about?
NCT02736656 is a clinical study titled "Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)". Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
What is the current status of trial NCT02736656?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,400 participants. The study started on 2016-02-02. Estimated completion is 2026-09.
What conditions does trial NCT02736656 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT02736656?
The interventions under investigation include: SPN-812 (DRUG).
Who is sponsoring clinical trial NCT02736656?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02736656 being conducted?
This trial has 16 study locations across Arkansas, California, Colorado, Florida, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Focus Groups in Ethnically and Racially Diverse Families
RECRUITING
-
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
RECRUITING · NA
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.